Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2024, and provided recent business ...

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a proffered paper session for prostate ...

@zklaassen_md on Twitter during the 2024 European Society of Medical Oncology (ESMO) Annual Meeting, Barcelona, Spain, Fri, Sept 13 – Tues, Sept 17, 2024.

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Fecal microbiota transplantation has significantly improved progression-free survival in patients with metastatic renal cell ...

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...